Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. More Details
Flawless balance sheet and slightly overvalued.
Share Price & News
How has Zealand Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ZEAL is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ZEAL's weekly volatility (6%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: ZEAL underperformed the Danish Biotechs industry which returned 43.9% over the past year.
Return vs Market: ZEAL underperformed the Danish Market which returned 38.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Zealand Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 weeks ago | Simply Wall StSome Zealand Pharma A/S (CPH:ZEAL) Analysts Just Made A Major Cut To Next Year's Estimates
1 month ago | Simply Wall StIs Zealand Pharma's (CPH:ZEAL) 113% Share Price Increase Well Justified?
3 months ago | Simply Wall StWhat You Need To Know About Zealand Pharma A/S' (CPH:ZEAL) Investor Composition
Is Zealand Pharma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ZEAL (DKK207.4) is trading below our estimate of fair value (DKK1207.02)
Significantly Below Fair Value: ZEAL is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ZEAL is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: ZEAL is unprofitable, so we can't compare its PE Ratio to the Danish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ZEAL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ZEAL's PB Ratio (6.7x) is in line with the DK Biotechs industry average.
How is Zealand Pharma forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ZEAL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ZEAL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ZEAL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ZEAL's revenue (39.2% per year) is forecast to grow faster than the Danish market (6.6% per year).
High Growth Revenue: ZEAL's revenue (39.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ZEAL is forecast to be unprofitable in 3 years.
How has Zealand Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ZEAL is currently unprofitable.
Growing Profit Margin: ZEAL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ZEAL is unprofitable, and losses have increased over the past 5 years at a rate of 21.6% per year.
Accelerating Growth: Unable to compare ZEAL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZEAL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.9%).
Return on Equity
High ROE: ZEAL has a negative Return on Equity (-68.88%), as it is currently unprofitable.
How is Zealand Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: ZEAL's short term assets (DKK1.4B) exceed its short term liabilities (DKK355.3M).
Long Term Liabilities: ZEAL's short term assets (DKK1.4B) exceed its long term liabilities (DKK177.4M).
Debt to Equity History and Analysis
Debt Level: ZEAL is debt free.
Reducing Debt: ZEAL has no debt compared to 5 years ago when its debt to equity ratio was 124.8%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZEAL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ZEAL has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 7.6% each year.
What is Zealand Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ZEAL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ZEAL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ZEAL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ZEAL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ZEAL's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Emmanuel Dulac (51 yo)
Dr. Emmanuel Dulac, PharmD, PhD, MBA, has been Chief Executive Officer at Zealand Pharma A/S since April 22, 2019 and its President since 2019. He had been Chief Commercial Officer and Senior Vice Presiden...
CEO Compensation Analysis
Compensation vs Market: Emmanuel's total compensation ($USD2.54M) is above average for companies of similar size in the Danish market ($USD1.45M).
Compensation vs Earnings: Insufficient data to compare Emmanuel's compensation with company performance.
Experienced Management: ZEAL's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: ZEAL's board of directors are considered experienced (9.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.8%.
Zealand Pharma A/S's company bio, employee growth, exchange listings and data sources
- Name: Zealand Pharma A/S
- Ticker: ZEAL
- Exchange: CPSE
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr.8.994b
- Shares outstanding: 43.36m
- Website: https://www.zealandpharma.com
Number of Employees
- Zealand Pharma A/S
- Sydmarken 11
- Capital Region of Denmark
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabo...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/12 17:15|
|End of Day Share Price||2021/04/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.